Nifty
Sensex
:
:
24090.85
76933.59
-116.90 (-0.48%)
-539.35 (-0.70%)

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 532872 | NSE: SPARC

194.98
27-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  194.69
  •  202.38
  •  192
  •  194.36
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  811811
  •  159412589.71
  •  289
  •  108

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,320.06
  • 3.99
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,875.04
  • N/A
  • 4.80

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 65.67%
  • 5.96%
  • 18.57%
  • FII
  • DII
  • Others
  • 3.9%
  • 0.08%
  • 5.82%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 26.36
  • 68.77
  • 191.91

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.04
  • 8.04
  • 8.04

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -13.40
  • -13.40
  • -13.40

Earnings Forecasts:

(Updated: 22-08-2026)
Description
2026
2027
2028
2029
Adj EPS
40
34
-
-
P/E Ratio
4.87
5.73
-
-
Revenue
-
-
-
-
EBITDA
-
-
-
-
Net Income
-
-
-
-
ROA
-
-
-
-
P/B Ratio
-
-
-
-
ROE
-
-
-
-
FCFF
-
-
-
-
FCFF Yield
-
-
-
-
Net Debt
-
-
-
-
BVPS
-
-
-
-

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
39.92
9.64
314.11%
1,853.22
27.19
6,715.81%
8.45
14.91
-43.33%
7.86
12.86
-38.88%
Expenses
73.92
61.72
19.77%
80.02
80.37
-0.44%
65.09
88.60
-26.53%
73.58
115.77
-36.44%
EBITDA
-34.00
-52.08
-
1,773.20
-53.18
-
-56.64
-73.69
-
-65.72
-102.91
-
EBIDTM
-85.17%
-540.25%
95.68%
-195.59%
-670.30%
-494.23%
-836.13%
-800.23%
Other Income
23.66
9.14
158.86%
1.80
0.00
0
0.00
0.19
-100.00%
0.01
0.04
-75.00%
Interest
8.13
6.19
31.34%
11.64
4.54
156.39%
8.78
2.80
213.57%
7.52
1.14
559.65%
Depreciation
2.20
2.68
-17.91%
2.40
2.95
-18.64%
2.57
3.14
-18.15%
2.56
3.16
-18.99%
PBT
-20.67
-51.81
-
1,760.96
-60.67
-
-80.35
-79.44
-
-75.79
-107.17
-
Tax
0.11
0.06
83.33%
-0.38
-0.90
-
0.07
0.07
0.00%
0.06
0.16
-62.50%
PAT
-20.78
-51.87
-
1,761.34
-59.77
-
-80.42
-79.51
-
-75.85
-107.33
-
PATM
-52.05%
-538.07%
95.04%
-219.82%
-951.72%
-533.27%
-965.01%
-834.60%
EPS
-0.64
-1.60
-
54.28
-1.84
-
-2.48
-2.45
-
-2.34
-3.31
-

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Net Sales
1,909.45
1,879.17
71.77
75.55
238.78
Net Sales Growth
2,855.80%
2518.32%
-5.00%
-68.36%
 
Cost Of Goods Sold
26.13
0.00
0.00
0.00
0.00
Gross Profit
1,883.32
1,879.17
71.77
75.55
238.78
GP Margin
98.63%
100%
100%
100%
100%
Total Expenditure
292.61
280.40
394.90
477.64
452.84
Power & Fuel Cost
-
6.26
6.33
6.14
5.75
% Of Sales
-
0.33%
8.82%
8.13%
2.41%
Employee Cost
-
118.02
153.58
141.84
107.00
% Of Sales
-
6.28%
213.99%
187.74%
44.81%
Manufacturing Exp.
-
56.00
114.52
140.23
180.31
% Of Sales
-
2.98%
159.57%
185.61%
75.51%
General & Admin Exp.
-
88.01
115.92
182.20
154.91
% Of Sales
-
4.68%
161.52%
241.16%
64.88%
Selling & Distn. Exp.
-
0.00
0.00
0.00
0.00
% Of Sales
-
0%
0%
0%
0%
Miscellaneous Exp.
-
12.11
4.55
7.23
4.87
% Of Sales
-
0.64%
6.34%
9.57%
2.04%
EBITDA
1,616.84
1,598.77
-323.13
-402.09
-214.06
EBITDA Margin
84.68%
85.08%
-450.23%
-532.22%
-89.65%
Other Income
25.47
10.95
1.79
29.47
10.88
Interest
36.07
34.13
9.04
1.69
7.63
Depreciation
9.73
10.21
12.39
12.51
11.77
PBT
1,584.15
1,565.37
-342.78
-386.83
-222.58
Tax
-0.14
-0.19
-0.27
0.38
0.00
Tax Rate
-0.01%
-0.01%
0.08%
-0.10%
0.00%
PAT
1,584.29
1,553.20
-342.51
-387.21
-222.58
PAT before Minority Interest
1,584.29
1,553.20
-342.51
-387.21
-222.58
Minority Interest
0.00
0.00
0.00
0.00
0.00
PAT Margin
82.97%
82.65%
-477.23%
-512.52%
-93.22%
PAT Growth
630.79%
-
-
-
 
EPS
48.82
47.86
-10.56
-11.93
-6.86

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Shareholder's Funds
1,338.83
-216.95
125.76
512.78
Share Capital
32.45
32.45
32.45
32.45
Total Reserves
1,306.37
-249.40
93.30
480.32
Non-Current Liabilities
75.68
175.93
122.97
138.41
Secured Loans
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
100.00
0.00
0.00
Long Term Provisions
12.34
7.68
6.05
8.14
Current Liabilities
754.11
374.24
265.06
178.95
Trade Payables
97.15
113.92
142.29
148.25
Other Current Liabilities
87.96
94.24
61.88
24.15
Short Term Borrowings
556.14
158.19
47.00
0.05
Short Term Provisions
12.85
7.89
13.89
6.49
Total Liabilities
2,168.62
333.22
513.79
830.14
Net Block
85.32
98.76
107.53
105.75
Gross Block
143.99
158.11
157.14
146.22
Accumulated Depreciation
58.67
59.35
49.60
40.47
Non Current Assets
306.18
307.03
244.39
375.16
Capital Work in Progress
71.71
54.15
43.79
27.00
Non Current Investment
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
120.63
128.19
67.67
64.80
Other Non Current Assets
28.52
25.93
25.40
177.61
Current Assets
1,862.43
26.20
269.39
454.96
Current Investments
0.00
0.00
1.80
290.90
Inventories
0.00
0.00
0.00
0.00
Sundry Debtors
8.27
16.06
15.53
32.71
Cash & Bank
1.16
1.96
155.33
111.58
Other Current Assets
1,853.00
4.20
42.24
3.98
Short Term Loans & Adv.
9.72
3.98
54.48
15.80
Net Current Assets
1,108.32
-348.04
4.33
276.02
Total Assets
2,168.61
333.23
513.78
830.12

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Cash From Operating Activity
-238.78
-360.29
-429.19
-69.12
PBT
1,553.01
-342.78
-386.83
-222.58
Adjustment
41.16
20.52
-10.91
6.99
Changes in Working Capital
-1,864.59
-46.86
-27.33
141.11
Cash after chg. in Working capital
-270.42
-369.12
-425.08
-74.48
Interest Paid
0.00
0.00
0.00
0.00
Tax Paid
31.64
8.83
-4.11
5.37
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
Cash From Investing Activity
-23.50
157.66
391.53
-548.28
Net Fixed Assets
-8.85
-11.19
-22.44
Net Investments
-0.01
1.80
288.68
Others
-14.64
167.05
125.29
Cash from Financing Activity
261.39
199.26
42.41
616.76
Net Cash Inflow / Outflow
-0.89
-3.38
4.74
-0.64
Opening Cash & Equivalents
1.96
5.33
0.58
1.22
Closing Cash & Equivalent
1.16
1.96
5.33
0.58

Financial Ratios

Standalone /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Book Value (Rs.)
41.25
-6.68
3.88
15.80
ROA
124.17%
-80.88%
-57.63%
-26.81%
ROE
276.89%
0.00%
-121.28%
-43.41%
ROCE
163.94%
-311.92%
-112.35%
-41.91%
Fixed Asset Turnover
12.44
0.46
0.50
1.63
Receivable days
2.36
80.33
116.55
50.01
Inventory Days
0.00
0.00
0.00
0.00
Payable days
0.00
0.00
0.00
0.00
Cash Conversion Cycle
2.36
80.33
116.55
50.01
Total Debt/Equity
0.42
-1.19
0.37
0.00
Interest Cover
46.50
-36.92
-227.27
-28.15

News Update:


  • Sun Pharma Adv. Res - Quarterly Results
    11th Aug 2026, 00:00 AM

    Read More
  • SPARC’s licensing partner receives Complete Response Letter from USFDA
    20th May 2026, 12:00 PM

    Ocuvex Therapeutics Inc. has received a Complete Response Letter for the PDP-716 New Drug Application

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.